



Peninsula Cancer Alliance

# **Clinical Guideline Statement**

## **Haematology Site Specific Group**

### VERSION CONTROL

THIS IS A CONTROLLED DOCUMENT - PLEASE ARCHIVE ALL PREVIOUS VERSIONS ON RECEIPT OF THE CURRENT VERSION.

Please check the Peninsula Cancer Alliance website for the latest available version:

<https://peninsulacanceralliance.nhs.uk/site-specific-groups/haemato-oncology-ssg/>

The Haematology SSG will evaluate and update these guidelines on an annual basis, via the PCA SSG meetings, taking into account advancements and/or changes to relevant healthcare policies/clinical guidelines and evidence based research.

It is expected that all Trusts within the Peninsula Cancer Alliance will be able to meet the standards of care recommended within these guidelines.

VERSION	DATE ISSUED	SUMMARY OF CHANGE	OWNER
0.1	JANUARY 2020	First draft	PCA Haematology SSG
0.2	SEPTEMBER 2020	Second Draft	PCA Haematology SSG
1.0	FEBRUARY 2022	Final Agreed	PCA Haematology SSG
2.0	MAY 2024 ( DRAFT)	EDITS – added MARIETTA and statement on CNS Prophylaxis in high grade lymphoma. Updated CLL pathway and Subspecialty leads added	PCA Haematology SSG
3.0	AUGUST 2024	Changes above agreed	PCA Haematology SSG

This document has been prepared by:

Beth Kingshott, Peninsula Cancer Alliance SSG Support Manager

These clinical guidelines have been agreed on behalf of the PCA Haematology SSG:

Name	Position	Organisation	Date agreed
Dr Jason Coppel	Consultant Haematologist	Royal Devon and Exeter NHS Foundation Trust	<b>August 2024</b>
		Northern Devon Healthcare NHS Trust	
Dr Michelle Furtado (SSG Chair)	Consultant Haematologist	Royal Cornwall Hospitals NHS Trust	<b>August 2024</b>

Dr Hannah Hunter	Consultant Haematologist	Plymouth Hospitals NHS Trust	August 2024
Dr Heather Eve (SSG Chair)	Consultant Haematologist	Torbay and South Devon NHS Foundation Trust	August 2024

## Clinical Guidelines

The Peninsula Cancer Alliance Haematology SSG refers to the following protocols for the management of Haematological cancers/ disorders;

### **Thames Valley Strategic Clinical Network Site Specific Group Protocols**

<http://nssg.oxford-haematology.org.uk/>

*NB: These guidelines are used as a reference only at the clinician's responsibility. The Peninsula Cancer Alliance Haematology SSG has not contributed to the preparation of these protocols.*

### **Generic Guidelines**

The PCA Haematology SSG also refers to the following generic guidelines produced by the National Institute for Health and Care Excellence (NICE) as a framework to inform the delivery of evidence based care to Haematological cancer patients;

- National Institute for Health and Care Excellence. (2016). *Haematological Cancers: Improving Outcomes* [NG47]. <https://www.nice.org.uk/guidance/ng47>

**MARIETTA Protocol** – all trusts have confirmed that they are using this protocol.

[https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026\(20\)30366-5/fulltext](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(20)30366-5/fulltext)

The PCA Haematology SSG also refers to the following regionally agreed pathways:

[Royal Cornwall Hospital, CLL Pathways, 2024](#)

[Royal Cornwall Hospital. Lymphoma Treatment Pathways, 2019 \(revised 2022\) V 9.0](#)

### **CNS Prophylaxis in high grade lymphoma**

The SSG has agreed to stop routinely offering high dose methotrexate for CNS Prophylaxis except for ultra-high-risk patients and/or based on a clinical discussion with the patient.

### Sub-Speciality Leads

The PCA Haematology SSG has allocated sub-speciality leads from across the Peninsula who can be contacted for specialist advice/ guidance and support.

[PCA Haem SSG Sub-Speciality Leads, 2022 V2.0.pdf](#)

### Clinical Trials

The PCA Haematology SSG is committed to offering all eligible patient entry into clinical trials where available. There are clinical trials open in each centre. Please liaise with the Research and Development department.